(19 November 2025, Hong Kong) Templewater is thrilled to announce that it has been awarded “Deal of the Year (Mid Cap)” at the AVCJ Private Equity & Venture Capital Awards 2025. The award recognizes Templewater’s take-private of TalkMED Group Limited, a transaction sourced, structured and executed by Templewater’s investment team, in partnership with Tamarind Health’s leading doctors and management team.
The TalkMED take‑private reflects Templewater’s differentiated approach to control investing: originating proprietary opportunities, aligning interests, and coordinating a complex, multi‑jurisdictional execution from diligence through financing and regulatory approvals. Post‑transaction, Templewater consolidated complementary practices under a single platform to accelerate growth and operational excellence.
Today, Tamarind Health’s network spans 36 outpatient and hospital‑based centers across Singapore, Hong Kong, Malaysia, the Philippines, Vietnam, and Mainland China, housing 140+ resident and visiting doctors who receive 180,000+ patient visits per annum. The platform includes OncoCare, TalkMED, Solis, Luma, Novena Heart Centre, Tamarind Specialists, and Can‑Care.
“We are honored by this recognition from AVCJ,” said Simon Chuk, Partner at Templewater. “This deal showcases Templewater’s ability to originate and execute complex transactions, partner with founders, and build a market leading platform through hands‑on ownership. We are grateful to our management team and advisors for their collaboration, and we especially thank all of our doctors in placing their trust in Templewater’s vision to build Tamarind Health.”
About Templewater
Templewater is an Asia-based alternative asset manager founded in 2018. The firm provides its investors, which include global institutions, family offices and high-net-worth individuals, with two core pan-Asia strategies: (a) private equity focusing on mid-market buyout, and (b) decarbonization and energy transition growth equity. Templewater’s mission is to provide financial and human capital, operational expertise, a corporate governance framework, and integrity to build leading businesses.
To learn more, please visit www.templewater.com and follow Templewater on LinkedIn at www.linkedin.com/company/templewater
About Tamarind Health
Tamarind Health is Asia’s leading integrated oncology-focused group, uniting renowned practices across the region to elevate care and improve patient outcomes. Headquartered in Singapore, the doctor-led platform brings together specialists across the full spectrum of oncology, from diagnostics and treatment to survivorship and well-being.
Our journey began with the acquisition of OncoCare Singapore and Novena Heart Centre, laying the foundation of our oncology and cardiac expertise. This foundation was broadened with Solis, Luma, OncoCare Philippines, and Can-Care, expanding our focus into breast care and post-care services. The network subsequently grew to include OncoCare Malaysia, OncoCare Hong Kong, and Tamarind Specialists, strengthening our regional presence. Most recently, the addition of TalkMED strengthened our presence in Singapore and extended our reach to Vietnam and Mainland China, further enhancing our scale and depth of expertise across Asia.
With the purpose of setting new standards in healthcare for better results, Tamarind Health is shaping the future of oncology and related services across six markets: Singapore, Hong Kong, Malaysia, the Philippines, Vietnam, and Mainland China.
We Believe in Better.
For more information, visit: https://tamarindhealth.com
Media Contact
Templewater Investor Relations
ir@templewater.com
+852 3187 5000
